Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe

International Journal of Antimicrobial Agents

Volumn 48, Issue 2, 2016, Pages 127-136

  Nathwani, Dilip ^a   Dryden, Matthew ^b   Garau, Javier ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^c HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

Antibiotic treatment; Clinical assessment; Early discharge; Skin and soft tissue infection

Indexed keywords

AZTREONAM; BETA LACTAMASE INHIBITOR; CEFTAROLINE; CEFTRIAXONE; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; LINEZOLID; ORITAVANCIN; PENICILLIN G; TEDIZOLID; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP; BONE MARROW SUPPRESSION; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DRUG APPROVAL; DRUG COST; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; LENGTH OF STAY; MEDICATION COMPLIANCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEUTROPHIL COUNT; OUTPATIENT CARE; OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY; PATIENT PREFERENCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL DRAINAGE; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT RESPONSE; DRUG MONITORING; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TIME FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG MONITORING; EUROPE; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84973101037     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.04.023     Document Type: Review

References (84)

1. [1] Dryden, M.S., Complicated skin and soft tissue infection. J Antimicrob Chemother 65:Suppl. 3 (2010), iii35–44.
2. [2] Stevens, D.L., Bisno, A.L., Chambers, H.F., Dellinger, E.P., Goldstein, E.J., Gorbach, S.L., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59 (2014), e10–52.
3. [3] Montravers, P., Snauwaert, A., Welsch, C., Current guidelines and recommendations for the management of skin and soft tissue infections. Curr Opin Infect Dis 29 (2016), 131–138.
4. [4] US Food and Drug Administration, Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. 2013, FDA, Rockville, MD.
5. [5] European Centre for Disease Prevention and Control, Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2011–2012. 2013, ECDC, Stockholm, Sweden http://www.ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf accessed 20.01.15.
6. [6] Phoenix, G., Das, S., Joshi, M., Diagnosis and management of cellulitis. BMJ, 345, 2012, e4955.
7. [7] Sader, H.S., Farrell, D.J., Jones, R.N., Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. Int J Antimicrob Agents 36 (2010), 28–32.
8. [8] Garau, J., Ostermann, H., Medina, J., Avila, M., McBride, K., Blasi, F., et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 19 (2013), E377–85.
9. [9] US Food and Drug Administration, Guidance for industry. Uncomplicated and complicated skin and skin structure infections—developing antimicrobial drugs for treatment. 1998, FDA, Rockville, MD.
10. [10] European Centre for Disease Prevention and Control, Antimicrobial resistance surveillance in Europe 2014. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). 2015, ECDC, Stockholm, Sweden.
11. [11] Hatoum, H.T., Akhras, K.S., Lin, S.J., The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis 64 (2009), 305–310.
12. [12] Ostermann, H., Blasi, F., Medina, J., Pascual, E., McBride, K., Garau, J., et al. Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups: the REACH study. J Med Econ 17 (2014), 719–729.
13. [13] Nathwani, D., Eckmann, C., Lawson, W., Solem, C.T., Corman, S., Stephens, J.M., et al. Influence of real-world characteristics on outcomes for patients with methicillin-resistant staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe. BMC Infect Dis, 14, 2014, 476.
14. [14] De Cock, E., Sorensen, S., Levrat, F., Besnier, J.M., Dupon, M., Guery, B., et al. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France. Med Mal Infect 39 (2009), 330–340.
15. [15] Public Health England, Start smart—then focus: antimicrobial stewardship toolkit for English hospitals. 2015, Public Health England, London, UK.
16. [16] Dryden, M., Saeed, K., Townsend, R., Winnard, C., Bourne, S., Parker, N., et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother 67 (2012), 2289–2296.
17. [17] Gray, A., Dryden, M., Charos, A., Antibiotic management and early discharge from hospital: an economic analysis. J Antimicrob Chemother 67 (2012), 2297–2302.
18. [18] Eckmann, C., Lawson, W., Nathwani, D., Solem, C.T., Stephens, J.M., Macahilig, C., et al. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents 44 (2014), 56–64.
19. TM summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002840/WC500183869.pdf accessed 10.08.15.
20. ® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002846/WC500184802.pdf accessed 10.08.15.
21. ® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003785/WC500186343.pdf accessed 10.08.15.
22. [22] Boucher, H.W., Wilcox, M., Talbot, G.H., Puttagunta, S., Das, A.F., Dunne, M.W., Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370 (2014), 2169–2179.
23. [23] Corey, G.R., Kabler, H., Mehra, P., Gupta, S., Overcash, J.S., Porwal, A., et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 370 (2014), 2180–2190.
24. [24] Moran, G.J., Fang, E., Corey, G.R., Das, A.F., De Anda, C., Prokocimer, P., Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structureinfections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 14 (2014), 696–705.
25. [25] Prokocimer, P., De Anda, C., Fang, E., Mehra, P., Das, A., Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309 (2013), 559–569.
26. ® summary of product characteristics. 2014, Novartis Pharmaceuticals, Camberley, UK.
27. ® summary of product characteristics. 2014, Sanofi, Guildford, UK.
28. [28] Hospira UK Ltd., Vancomycin summary of product characteristics. 2009, Hospira UK Ltd., Leamington Spa, UK.
29. ® summary of product characteristics. 2014, Pfizer, Sandwich, UK.
30. [30] Sartelli, M., Malangoni, M.A., May, A.K., Viale, P., Kao, L.S., Catena, F., et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg, 9, 2014, 57.
31. [31] Ki, V., Rotstein, C., Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol 19 (2008), 173–184.
32. [32] Marwick, C., Broomhall, J., McCowan, C., Phillips, G., Gonzalez-McQuire, S., Akhras, K., et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. J Antimicrob Chemother 66 (2011), 387–397.
33. [33] Marwick, C., Rae, N., Irvine, N., Davey, P., Prospective study of severity assessment and management of acute medical admissions with skin and soft tissue infection. J Antimicrob Chemother 67 (2012), 1016–1019.
34. [34] National Institute for Health and Clinical Excellence, Surgical site infection prevention and treatment of surgical site infection. 2014, NICE.
35. [35] Esposito, S., Bassetti, M., Borrè, S., Bouza, E., Dryden, M., Fantoni, M., et al. Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. J Chemother 23 (2011), 251–262.
36. [36] Gould, F.K., Brindle, R., Chadwick, P.R., Fraise, A.P., Hill, S., Nathwani, D., et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 63 (2009), 849–861.
37. [37] Nathwani, D., Morgan, M., Masterton, R.G., Dryden, M., Cookson, B.D., French, G., et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 61 (2008), 976–994.
38. [38] Pan, A., Cauda, R., Concia, E., Esposito, S., Sganga, G., Stefani, S., et al. Consensus document on controversial issues in the treatment of complicated skin and skin-structure infections. Int J Infect Dis 14:Suppl. 4 (2010), S39–53.
39. ® summary of product characteristics. 2014, Pfizer, Sandwich, UK.
40. [40] Schofer, H., Bruns, R., Effendy, I., Hartmann, M., Jappe, U., Plettenberg, A., et al. Diagnosis and treatment of Staphylococcus aureus infections of the skin and mucous membranes. J Dtsch Dermatol Ges 9 (2011), 953–967.
41. [41] Bassetti, M., Baguneid, M., Bouza, E., Dryden, M., Nathwani, D., Wilcox, M., European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 20:Suppl. 4 (2014), 3–18.
42. [42] Dryden, M.S., Novel antibiotic treatment for skin and soft tissue infection. Curr Opin Infect Dis 27 (2014), 116–124.
43. [43] Dryden, M.S., Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection?. Curr Opin Infect Dis 28 (2015), 117–124.
44. ® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002252/WC500132586.pdf accessed 10.08.15.
45. [45] Berger, A., Oster, G., Edelsberg, J., Huang, X., Weber, D.J., Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect (Larchmt) 14 (2013), 304–312.
46. [46] Lipsky, B.A., Napolitano, L.M., Moran, G.J., Vo, L., Nicholson, S., Chen, S., et al. Economic outcomes of inappropriate initial antibiotic treatment for complicated skin and soft tissue infections: a multicenter prospective observational study. Diagn Microbiol Infect Dis 79 (2014), 266–272.
47. [47] Eagye, K.J., Kim, A., Laohavaleeson, S., Kuti, J.L., Nicolau, D.P., Surgical site infections: does inadequate antibiotic therapy affect patient outcomes?. Surg Infect (Larchmt) 10 (2009), 323–331.
48. [48] Edelsberg, J., Berger, A., Weber, D.J., Mallick, R., Kuznik, A., Oster, G., Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 29 (2008), 160–169.
49. [49] Garau, J., Blasi, F., Medina, J., McBride, K., Ostermann, H., Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study. BMC Infect Dis, 15, 2015, 78.
50. [50] Dryden, M., Andrasevic, A.T., Bassetti, M., Bouza, E., Chastre, J., Baguneid, M., et al. Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey. Int J Antimicrob Agents 45:Suppl. 1 (2015), S1–14.
51. [51] Gilchrist, M., Seaton, R.A., Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklists. J Antimicrob Chemother 70 (2015), 965–970.
52. [52] Howard, P., Pulcini, C., Levy, H.G., West, R.M., Gould, I.M., Harbarth, S., et al. An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. J Antimicrob Chemother 70 (2015), 1245–1255.
53. [53] Hensher, M., Edwards, N., Hospital provision, activity, and productivity in England since the 1980s. BMJ 319 (1999), 911–914.
54. [54] Nathwani, D., Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?. J Antimicrob Chemother 51:Suppl. 2 (2003), ii37–44.
55. [55] Nathwani, D., Health economic issues in the treatment of drug-resistant serious Gram-positive infections. J Infect 59:Suppl. 1 (2009), S40–50.
56. [56] Chapman, A.L., Seaton, R.A., Cooper, M.A., Hedderwick, S., Goodall, V., Reed, C., et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother 67 (2012), 1053–1062.
57. [57] Matthews, P.C., Conlon, C.P., Berendt, A.R., Kayley, J., Jefferies, L., Atkins, B.L., et al. Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother 60 (2007), 356–362.
58. [58] Tice, A.D., Rehm, S.J., Dalovisio, J.R., Bradley, J.S., Martinelli, L.P., Graham, D.R., et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 38 (2004), 1651–1672.
59. [59] Seaton, R.A., Sharp, E., Bezlyak, V., Weir, C.J., Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int J Antimicrob Agents 38 (2011), 243–248.
60. [60] Mertz, D., Koller, M., Haller, P., Lampert, M.L., Plagge, H., Hug, B., et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother 64 (2009), 188–199.
61. [61] Nathwani, D., Eckmann, C., Lawson, W., Stephens, J.M., Macahilig, C., Solem, C.T., et al. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin Microbiol Infect 20 (2014), 993–1000.
62. [62] Itani, K.M., Shorr, A.F., FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials. Clin Infect Dis 58:Suppl. 1 (2014), S4–9.
63. [63] European Medicines Agency, Addendum to the guidelines on the evaluation of medicinal products indicated for treatment of bacterial infections. 2013, Committee for Human Medicinal Products (CHMP).
64. [64] Toerner, J.G., Burke, L., Komo, S., Papadopoulos, E., A collaborative model for endpoint development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. Clin Infect Dis 55 (2012), 1122–1123.
65. [65] Shorr, A.F., Lodise, T.P., Corey, G.R., De Anda, C., Fang, E., Das, A.F., et al. Analysis of the phase 3 ESTABLISH trials: tedizolid versus linezolid in acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 59 (2015), 864–871.
66. [66] Corey, G.R., Good, S., Jiang, H., Moeck, G., Wikler, M., Green, S., et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 60 (2015), 254–262.
67. [67] Friedland, H.D., O'Neal, T., Biek, D., Eckburg, P.B., Rank, D.R., Llorens, L., et al. CANVAS 1 and 2: analysis of clinical response at Day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 56 (2012), 2231–2236.
68. [68] US Food and Drug Administration, Draft guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. 2010, FDA, Rockville, MD.
69. [69] Corey, G.R., Good, S., Jiang, H., Moeck, G., Wikler, M., SOLO 1 and SOLO II Investigators. Concordance between early and late clinical response with a single dose of oritavancin in the SOLO studies. 54th interscience conference on antimicrobial agents and chemotherapy (ICAAC); 5–9 September 2014, 2014, ASM Press, Washington, DC abstract F-972.
70. [70] Dunne M.W., Puttagunta S., Wilcox M., Tasaki O., Boucher H.W., FIDSA. Concordance of clinical response at 48–72 hours after initiation of therapy and end of therapy (EOT) in patients with acute bacterial skin and skin structure infection (ABSSSI) in the DISCOVER studies. In: IDWeek 2013; 2–6 October 2013; San Francisco, CA, abstract 1340.
71. [71] Wong, E., Rab, S., Tedizolid phosphate (Sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections. P T 39 (2014), 555–579.
72. [72] Das, A., Corey, R., Nathwani, D., Sandison, T., De Anda, C., Prokocimer, P., Does early clinical response predict late clinical success in patients with acute bacterial skin and skin structure infections (ABSSSI)? Data from the ESTABLISH clinical trials. 25th European congress of clinical microbiology and infectious diseases (ECCMID); 25–28 April 2015, 2015, ESCMID, Copenhagen, Denmark. Basel, Switzerland abstract EV0362.
73. [73] Infectious Diseases Society of America, IDSA comments on FDA's draft guidance for industry on acute bacterial skin and skin structure infections (ABSSSI). http://www.idsociety.org/uploadedFiles/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Advancing_Product_Research_and_Development/Bad_Bugs_No_Drugs/Position_Papers/IDSA%20Comments%20re%20FDA%20ABSSSI%20Guidance%20111710.pdf accessed 01.08.15.
74. [74] Goldberg, E., Paul, M., Talker, O., Samra, Z., Raskin, M., Hazzan, R., et al. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. J Antimicrob Chemother 65 (2010), 1779–1783.
75. [75] Cotrimoxazole versus vancomycin for invasive methicillin-resistant Staphylococcus aureus infections. https://clinicaltrials.gov/ct2/show/NCT00427076 accessed 12.02.15.
76. [76] Marra, C.A., Frighetto, L., Goodfellow, A.F., Wai, A.O., Chase, M.L., Nicol, R.E., et al. Willingness to pay to assess patient preferences for therapy in a Canadian setting. BMC Health Serv Res, 5, 2005, 43.
77. [77] Bamford, K.B., Desai, M., Aruede, M.J., Lawson, W., Jacklin, A., Franklin, B.D., Patients' views and experience of intravenous and oral antimicrobial therapy: room for change. Injury 42:Suppl. 5 (2011), S24–7.
78. [78] Vrijens, B., Urquhart, J., Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother 55 (2005), 616–627.
79. [79] Cals, J.W., Hopstaken, R.M., Le Doux, P.H., Driessen, G.A., Nelemans, P.J., Dinant, G.J., Dose timing and patient compliance with two antibiotic treatment regimens for lower respiratory tract infections in primary care. Int J Antimicrob Agents 31 (2008), 531–536.
80. [80] Kardas, P., Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother 59 (2007), 531–536.
81. [81] Llor, C., Sierra, N., Hernandez, S., Moragas, A., Hernandez, M., Bayona, C., et al. The higher the number of daily doses of antibiotic treatment in lower respiratory tract infection the worse the compliance. J Antimicrob Chemother 63 (2009), 396–399.
82. [82] Kardas, P., Once-daily dosage secures better compliance with antibiotic therapy of respiratory tract infections than twice-daily dosage. J Appl Res 3 (2014), 2001–2006.
83. [83] Kauf, T., Adults' adherence with anti-infectives. White paper. 2014, Cubist Pharmaceuticals, Lexington, MA.
84. [84] Eron, L.J., Lipsky, B.A., Low, D.E., Nathwani, D., Tice, A.D., Volturo, G.A., Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 52:Suppl. 1 (2003), i3–17.